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Background: The purpose of this study was to evaluate the use of intralesional propranolol 
injection in the management of periocular capillary hemangioma.
Methods: A prospective study was performed in 22 consecutive patients with periocular 
hemangioma. Twelve patients underwent intralesional propranolol injection and ten patients 
underwent intralesional triamcinolone injection. The size of the lesion was measured serially 
every week during the first month, every 2 weeks for the second month, and then monthly for 
another 2 months. The refractive error and degree of ptosis if present were measured before 
injection and at the end of the study.
Results: There was reduction in the size of hemangioma, astigmatic error, and degree of ptosis 
in both groups. The difference in outcome between both groups was not statistically significant. 
Rebound growth occurred in 25% of the propranolol group and 30% of the steroid group but 
responded to reinjection. No adverse effects were reported during or after intralesional propra-
nolol injection.
Conclusion: Intralesional propranolol injection is an alternative and effective method for 
treatment of infantile periocular hemangioma.
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Introduction
Hemangiomas are the most common tumors of the eyelids and orbit in children.1 They 
typically appear at or shortly after birth, with approximately 90% being clinically 
obvious by 2 months of age.2 Hemangiomas usually exhibit an initial phase of progres-
sive growth followed by spontaneous regression, and 70% regress completely by the 
age of 7 years.3
Despite the usually benign and self-limiting course of periocular hemangiomas, 
functional and cosmetic sequelae may persist. Periocular hemangiomas can pose a 
threat to visual development through anisometropia, amblyopia, or impairment of the 
visual axis. Hemangiomas can also be complicated by dermatologic problems, such 
as residual telangiectasias, scarring, and facial disfigurement that can negatively impact 
emotional development.2
There are different modalities for management of periocular capillary heman-
giomas. The most commonly used treatment modalities have been intralesional or 
systemic corticosteroids.4 Other treatment options include interferon alpha,5 vincristine,6 
laser therapy,7 or surgical excision.8
Recently, oral propranolol, a nonselective beta-blocker, has been shown to inhibit 
vascular proliferation of capillary hemangioma.9–12 However, such therapy requires Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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administration of systemic propranolol for at least 2 months, 
with possible side effects requiring careful clinical 
  monitoring. In addition, various complications have been 
reported with systemic propranolol therapy.13–16
A few studies have investigated the use of topical beta-
blockers for treatment of capillary hemangioma, and have 
reported good results with topical application.17,18 Such reports 
have raised the possibility of using direct intralesional beta-
blockers for treatment of capillary hemangioma. Propranolol 
is available in both oral and parenteral forms. In the present 
study, we attempted to investigate the effect of direct intral-
esional propranolol injection in periocular hemangioma. 
Because corticosteroids have been the gold standard of treat-
ment for capillary hemangioma for a long time, we used 
intralesional steroid injection in another subset of patients 
who served as a control group.
Materials and methods
The study protocol was approved by the hospital ethics 
  committee. The study and data collection conformed to all 
local laws and were compliant with the principles of the 
Declaration of Helsinki. The parent or guardian of each study 
patient gave their written informed consent.
This prospective study was performed in patients with 
periocular hemangiomas requiring intervention. The main 
indications for intervention included visual-threatening capil-
lary hemangioma, or rapidly progressive or recurrently 
bleeding hemangioma. Vision-threatening hemangiomas 
were defined as hemangiomas causing obstruction of the 
visual axis or inducing astigmatism, strabismus, amblyopia, 
or anisometropia. In addition, hemangiomas likely to lead to 
cosmetic deformity in the future or causing psychologic 
distress to the parents were included.
Any child with cardiovascular problems, bronchial 
asthma, or diabetes mellitus was excluded. Children who had 
had previous treatment for hemangioma were also excluded. 
Prior to inclusion, all patients were subjected to a detailed 
cardiac evaluation, including history-taking, detailed clinical 
examination, and a 12-lead electrocardiogram, including 
calculation of heart rate, voltages, and intervals.
intralesional injection
The first ten patients received an intralesional steroid injec-
tion of triamcinolone 40 mg/mL. The next twelve patients 
received an intralesional propranolol injection 1 mg/mL. 
The volume of injected drug depended on the size of the 
lesion (0.2 mL injected per cm of lesion diameter), with a 
maximum volume of 1 mL for a lesion of 5 cm diameter. 
All patients had undiluted injections under general inhalation 
anesthesia with cardiovascular and respiratory monitoring 
during and after injection. In addition, a dilated fundus 
examination was done during injection, with careful exami-
nation of the central retinal artery.
Patients who underwent intralesional steroid injection 
were discharged a few hours after injection. Patients who 
underwent intralesional propranolol injection were kept 
under observation for the first 24 hours, during which blood 
pressure and heart rate were measured at hourly intervals. 
Blood glucose was measured if clinically indicated based on 
symptoms of clamminess, distress, or irritability.
Follow-up
Patients were followed up on a weekly basis for the first month, 
then every 2 weeks in the second month, and finally at 
4-weekly intervals for a period of 4 months after the   injection. 
The patients were followed up by an investigator blinded to 
the drug injected. The size of the hemangioma was measured 
by clinical examination and documented by serial photography. 
The area was then calculated in mm2 and   measured serially. 
The response to intralesional therapy was graded as excellent, 
good, fair, or poor, according to the final outcome achieved 
at the time treatment was stopped (Table 1). Patients with 
rebound growth after resolution were   documented. In addition, 
cycloplegic refraction was performed for all patients before 
initiation of therapy and at the end of the study. The degree 
of ptosis was assessed by comparing the maximum palpebral 
fissure height on both sides before initiation of therapy and 
at the end of the follow-up period.
statistical analysis
Changes in each group were analyzed using repeated- 
measures analysis of variance. Differences between the groups 
were analyzed using the t-test for independent samples. 
Statistical analyses were carried out using StatLab, SPSS for 
Windows (v 16.0; SPSS, Inc, Chicago, IL).
Results
A total of 22 patients were included in the study. The mean 
age at treatment was 5.9 months ± 2.7 months in the 
Table  1  Grading  system  used  in  evaluation  of  intralesional 
injection for treatment of periocular hemangiomas
Grade Response achieved
excellent Complete resolution achieved
Good sustained plateau, with $50% reduction in size of hemangioma
Fair sustained plateau, with ,50% reduction in size of hemangioma
Poor No response or worsening of hemangiomaClinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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propranolol group and 6.1 months ± 2.9 months in the steroid 
group (P = 0.45). The main indication for treatment was 
vision-threatening hemangioma. Other indications for treat-
ment are listed in Table 2.
Outcome of propranolol treatment
Ten of twelve patients (83%) in the propranolol group showed 
regression of hemangioma (Table 3). Regression was noted 
in the first 24 hours in two patients. In the   remaining eight 
patients, onset of regression varied from 1 to 3 weeks after the 
injection, so that all ten patients showed evidence of regression 
by the end of the third week.   Regression almost always started 
with a change in the   hemangioma color from intense red to 
lighter purple-blue, together with palpable softening of the 
lesion. After this initial response, hemangiomas continued to 
improve as regards regression of their size, flattening of the 
lesion, and more evident blanching of the color. At the end of 
the   follow-up period, 42% of patients (n = 5) showed an 
excellent final response (Figure 1), with almost complete 
resolution of the lesion, 25% (n = 3) showed a good response 
with more than 50% reduction in the size of the lesion 
(Figure 2), and 17% (n = 2) showed a fair response with less 
than 50% reduction in the size of the lesion. Only two patients 
(17%) were resistant to treatment. In general, patients with 
smaller hemangiomas tended to respond better to intralesional 
injection. However, it was difficult to analyze this relationship 
statistically because of the small number of patients.
Outcome of steroid treatment
Eight of ten patients in the intralesional steroid group showed 
regression of hemangioma (Table 3). Onset of regression 
was slightly more delayed than in the   propranolol group. 
Regression started to appear in the first week in one patient. 
In the remaining seven patients, the onset of regression varied 
from 2 to 3 weeks after injection. The clinical course of 
regression was similar to that in the propranolol group as 
regards change in color and regression in size and depth of 
the lesion. At the end of the follow-up period, 40% of patients 
(n = 4) showed an excellent final response with almost com-
plete resolution of the lesion, 20% (n = 2) showed a good 
response, and 20% (n = 2) showed a fair response. Two 
patients (20%) previously documented to be resistant to 
treatment showed a poor final response.
Change in refractive error
Of the 22 patients, twelve patients had significant astigmatism 
more than 1 D (mean = 2.1 ± 1.5 D). Four months after injection, 
there was a reduction in astigmatic error (mean = 1.3 ± 1.1 D). 
The reduction in astigmatic error was statistically significant 
in both the propranolol group (P = 0.02) and the steroid group 
(P = 0.03). There was no statistically significant difference in 
the final astigmatic error between both groups (P = 0.34).
Degree of ptosis
Fifteen patients had significant ptosis of more than 1 mm 
difference between the eyes (mean = 1.5 ± 1.4 mm). 
Table 2 indications for intervention in the present study
n (%)
Obstruction of visual axis 10 (45%)
induced astigmatism or anisometropia but no obstruction  
of visual axis
4 (18%)
rapidly progressive hemangioma 4 (18%)
Cosmetic disfigurement and/or causing parental distress 4 (18%)
Table 3 Changes in size of hemangioma after injection
Propranolol  
group
Steroid  
group
size of hemangioma before  
injection (cm2)  
Mean ± standard deviation, range
8.1 ± 3.4,  
range 3.6–14.3
7.9 ± 3.6,  
range 3.5–14.1
Final size of hemangioma  
after 4 months (cm2)  
Mean ± standard deviation, range
3.6 ± 2.6,  
range 0– 7.1
3.7 ± 2.5, 
range 0–7.5
A
B
Figure 1 Clinical photographs of a representative case showing a 4-month-old patient 
with periocular hemangioma. (A) initial photographs before injection and (B) 4 months 
after propranolol injection showing excellent response with almost complete resolution 
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Four months after injection, there was a reduction in the 
degree of ptosis (mean = 0.9 ± 1.1 mm). The reduction in 
degree of ptosis was statistically significant in both the 
  propranolol group (P = 0.02) and the steroid group (P = 0.02). 
There was no statistically significant difference in the degree 
of ptosis between the groups (P = 0.46).
rebound growth
Of the patients who showed evidence of regression with 
therapy, seven later showed evidence of rebound growth. 
This included four patients in the propranolol group and three 
patients in the steroid group (Table 4). Rebound growth 
occurred in the form of a sudden increase in size and 
worsening of color. All patients received reinjection and 
responded to treatment in a shorter duration than for the first 
time.   Reinjection was done using the same initial therapeutic 
agent given.
side effects
None of the patients developed local side effects during or 
after injection. Patients in the propranolol group had no 
significant change in heart rate or blood pressure during or 
after injection. However, we did not investigate and assess 
for possible systemic side effects of intralesional steroids, 
such as adrenal suppression.
Discussion
Capillary hemangioma occurs in about 10% of infants, with 
a predominance in females, premature infants and 
Caucasians.19 Capillary hemangiomas are characterized by 
rapid proliferation during the first year (proliferative phase), 
followed by slow involution over the next 5 years (involuting 
phase), during which cellular elements are replaced by fibro-
fatty deposition.20 However, functional or cosmetic sequelae 
may occur and require intervention.21
The use of intralesional corticosteroids to induce involu-
tion of capillary hemangiomas was first introduced in 
1982.22 Since then, steroids have remained the first-line 
treatment for infantile hemangioma in the vast majority of 
cases. However, adverse effects have been reported with 
intralesional steroids, in particular, skin changes and 
adrenal-related changes. Reported skin-related complica-
tions have included skin atrophy and/or necrosis, skin 
depigmentation, and fat atrophy. Adrenal-related changes 
are even more serious, and include reversible cushingoid 
facies, as well as adrenal suppression that may require 
replacement therapy.4 A serious complication, ie, central 
retinal artery occlusion, has also been reported with intral-
esional steroid injection.4
Table 4 summary of data on patients who developed rebound growth after cessation of therapy
Patient number Gender Age at start  
(months)
Treatment given Response Onset of relapse after 
injection (weeks)
1 F 3 steroids excellent 12
2 F 4 steroids Good 10
3 M 4 steroids Fair 10
4 M 5 Propranolol excellent 10
5 M 3 Propranolol Good 12
6 F 3 Propranolol Fair 12
7 F 3 Propranolol Fair 12
A
B
Figure 2 Clinical photographs of a representative case showing a 5-month-old 
patient with periocular hemangioma. (A) initial photographs before injection and (B) 
4 months after propranolol injection showing good response with marked reduction 
in size of the lesion.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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In 2008, Leatue-Labreze et al reported a dramatic effect 
of systemic propranolol in inducing accelerated involution of 
infantile hemangioma.9 There is as yet no generally accepted 
consensus on the ideal treatment regime for propranolol. The 
main differences between the different published reports were 
the dosage of propranolol used and the duration of 
treatment.10–12 The mechanism of action of propranolol in 
hemangiomas is unknown. It is speculated that it may act 
through increased apoptosis and downregulation of vascular 
endothelial growth factor as a result of vasoconstriction.23,24
Despite the initial promise that propranolol may replace 
oral corticosteroids as the treatment of choice for infantile 
hemangioma, there are many potential side effects of pro-
pranolol, including bradycardia, hypotension, hypoglycemia, 
rash, gastrointestinal discomfort/reflux, fatigue, and 
bronchospasm.13–16 Lethargy and hypothermia have also been 
reported, and required termination of therapy.13 Additionally, 
infants with PHACE syndrome with tortuous, aneurysmal, or 
stenotic intracranial arteries would potentially be at increased 
risk of stroke if treated with propranolol.24 Holmes et al10 and 
Leboulanger et al11 recommended that a full cardiovascular 
workup be performed prior to initiation of propranolol therapy, 
to identify patients in whom commencement of propranolol 
therapy could be dangerous. In addition, infants with large 
facial hemangioma should be evaluated for a PHACE 
association before initiation of oral propranolol.25
In this prospective clinical study, conducted on 22 con-
secutive patients with infantile hemangioma, intralesional 
propranolol was shown to be almost as effective as intrale-
sional steroids. Intralesional propranolol was not associated 
with significant cardiovascular changes or local adverse 
effects during or after injection. One may speculate, although 
not be able to prove it, that the systemic effects of direct 
intralesional injection may possibly be reduced by intralesional 
injection. Because hemangiomas are very vascular lesions, 
accidental systemic absorption may occur. The injection is 
done under general anesthesia with careful cardiovascular 
monitoring for immediate management if significant brady-
cardia or hypotension occurs. Atropine would be given in the 
event of such a complication. However, we did not encounter 
such complications during injection in our study. However, 
it is worth mentioning that we did not study the possible 
systemic side effects of intralesional steroids. The intrale-
sional steroid group only served as a control group to allow 
evaluation of our results, given that intralesional steroids are 
considered close to a gold standard therapy.
Despite the good efficacy of propranolol, relapses may 
occur. In this study, four patients (25%) showed evidence of 
rebound growth after cessation of therapy. All of these 
patients were younger than 5 months at the time of injection. 
This may be explained by the fact that, in the early months 
of life, capillary hemangioma is in its active proliferative 
phase when there are high levels of   proangiogenic factors. 
Later on, there may be a shift of balance towards proapoptotic 
factors, reducing the chance of rebound growth.20
Qin et al12 performed one of the largest studies to date 
using propranolol in 58 infants with infantile hemangioma 
at a dose of 1–1.5 mg/kg/day. They reported a response rate 
of “good to excellent” in 67% of patients. In our study, we 
achieved a similar response with intralesional propranolol 
injection. This suggests that direct intralesional injection of 
propranolol can achieve similar results to systemic propra-
nolol therapy. However, this would require adequate 
controlled double-blind studies to allow accurate comparison 
of the results.
Furthermore, we noted a significant reduction in astig-
matic error and degree of ptosis after injection. This is 
consistent with previous studies reporting improvement in 
refractive error after systemic propranolol therapy and after 
intralesional steroid therapy.26,27
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